^
Association details:
| Biomarker: | HER-2 expression |
|---|---|
| Cancer: | Gastrointestinal Cancer |
| Drug: | Keytruda (pembrolizumab) (PD1 inhibitor) + Margenza (margetuximab-cmkb) (HER2 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
EVALUATION OF TUMOR MICROENVIRONMENT IDENTIFIES IMMUNE CORRELATES OF RESPONSE TO COMBINATION IMMUNOTHERAPY WITH MARGETUXIMAB (M) AND PEMBROLIZUMAB (P) IN HER2+ GASTROESOPHAGEAL ADENOCARCINOMA (GEA)
Published date:
09/30/2019
Excerpt:
ERBB2 expression significantly correlated with response; pts with CR/PR had a 5.13 FC ERBB2 expression compared to PD (p < 0.001). Importantly, ERBB2 expression was associated with anti-tumor activity (ROC-AUC=0.754), with a 3.1 FC between SD/PR/CR vs PD (p = 0.004).
Trial ID:
